Zhaoke Ophthalmology (HKG:6622) entered into three distribution and supply agreements with Interpharma PCL (BKK:IP) to commercialize several ophthalmic drugs in Thailand, according to a Wednesday filing with the Hong Kong Exchange.
The deals cover NVK002 for myopia progression control, BRIMOCHOL PF for presbyopia, and six generic glaucoma drugs: Bimatoprost, Bimatoprost Timolol, Latanoprost, Latanoprost Timolol, Travoprost, and Travoprost Timolol.
Under the agreements, Interpharma gains exclusive rights to import, distribute, market, and sell Zhaoke's products in Thailand and will manage local drug registrations. Zhaoke will then receive non-refundable upfront payments and milestone-based payments.
Shares of Interpharma closed nearly 5% higher on Wednesday, while those of Zhaoke slipped 3%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。